Medicine & Life Sciences
Acute Myeloid Leukemia
14%
Adoptive Immunotherapy
15%
Agammaglobulinaemia Tyrosine Kinase
8%
axicabtagene ciloleucel
40%
B-Cell Chronic Lymphocytic Leukemia
16%
B-Cell Lymphoma
69%
Brentuximab Vedotin
28%
Cell- and Tissue-Based Therapy
18%
Chimeric Antigen Receptors
31%
Confidence Intervals
15%
Cyclophosphamide
16%
Cytokine Release Syndrome
8%
Dacarbazine
9%
Disease Progression
8%
Doxorubicin
16%
Drug Therapy
24%
Eye
11%
Follicular Lymphoma
24%
Graft vs Host Disease
8%
Heterogeneous-Nuclear Ribonucleoprotein K
15%
Hodgkin Disease
100%
Lenalidomide
31%
Lymphoma
43%
Lymphoma, Large B-Cell, Diffuse
29%
Mantle-Cell Lymphoma
40%
Multicenter Studies
8%
Neoplasms
15%
Neurotoxicity Syndromes
16%
Nivolumab
27%
Non-Hodgkin's Lymphoma
11%
PCI 32765
42%
pembrolizumab
21%
Peripheral T-Cell Lymphoma
18%
Phase II Clinical Trials
8%
Positron Emission Tomography Computed Tomography
13%
Progression-Free Survival
34%
Radiotherapy
37%
Recurrence
20%
Rituximab
56%
Safety
13%
Salvage Therapy
8%
Stem Cell Transplantation
16%
Survival
30%
Survival Rate
8%
Survivors
8%
T-Lymphocytes
17%
Therapeutics
24%
Transplants
11%
Vinblastine
8%
Vincristine
13%